

Table S5. Amyloid-β(1-40) (Aβ), aGSK3β and p-tau/total tau (pTau/tTau) detailed by patient, iPSC line and culture well

Patient	iPSC line	NPC line	Diff. plate*	FACS purification date	Aβ/lysate (pg/mg)†	Aβ purif. mean ‡	Aβ iPSC line mean §	Aβ patient mean¶	aGSK3β (% of total) †	aGSK3β purif. mean‡	aGSK3β iPSC line mean§	Active GSK3β patient mean¶	pTau/ tTau (units/ng)†	pTau/ tTau purif. mean‡	pTau/ tTau iPSC line mean§	pTau/ tTau patient mean¶						
NDC1	NDC1.1	NDC1.1.1	1.1	5/20/09	216.5	191.3	87.8	89.1		8.2	14.1			5.0	4.5							
			2.1		166.1																	
			3.1	3/19/10	0.0	2.2			10.8			8.2	3.7			5.0						
			4.1		6.4				7.8				3.7									
			5.1		2.2				6.1				6.0									
			6.1		0.0								6.6									
			7.1		9/30/10	147.4			132.9													
			8.1			154.8																
			9.1			96.6																
			NDC1.2	NDC1.2.1	1.1	10/8/09			34.6			68.1	71.3					14.9			4.5	
					2.1				0.0													
					3.1				95.0													
					3.2				143.0													
	4.1	9/23/10			83.3	71.9	16.6		14.9	4.1		4.5										
	5.1				85.5	15.5	4.8															
	6.1				59.0	12.6	4.7															
	6.2				59.8																	
	7.1				2/26/11	81.5	81.5							4.5								
	NDC1.3	NDC1.3.1			1.1	10/6/09	140.4		135.2	108.2						19.1				4.1		
			2.1	130.0																		
			3.1	10/7/10	96.8	99.5	17.0		19.1			4.3		4.1								
			4.1		70.8	18.9	4.1															
			5.1		118.7	21.5	4.1															
			5.2		111.6																	
			6.1		2/23/11	90.1	101.9											3.8				
			7.1	95.4																		
			8.1	120.1																		

\* Differentiation plate. First digit identifies the plate of NPCs differentiated for 3 weeks, prior to FACS purification. The second digit identifies the well of purified neurons that was cultured for an additional 5 days before harvesting  
† Observed amount for each corresponding well of purified neurons  
‡ Mean amount for each FACS purification batch  
§ Mean amount for each iPSC line (displayed in Supplementary Fig. 11)  
¶ Mean amount for each patient (displayed in Fig. 2 and Supplementary Table 4)

Table S5, continued

Patient	iPSC line	NPC line	Diff. plate*	FACS purification date	Aβ/lysate (pg/mg)†	Aβ purif. mean ‡	Aβ iPSC line mean §	Aβ patient mean¶	aGSK3β (% of total) †	aGSK3β purif. mean‡	aGSK3β iPSC line mean§	Active GSK3β patient mean¶	pTau/ tTau (units/ng)†	pTau/ tTau purif. mean‡	pTau/ tTau iPSC line mean§	pTau/ tTau patient mean¶			
NDC2	NDC2.1	NDC2.1.1	1.1	12/4/09	48.8	82.5	72.2	90.1	13.7	12.0	12.0	16.4	3.1	3.2	3.3	2.9			
			2.1		155.0				8.9				3.3						
			3.1		43.8				13.5				3.2						
			4.1	4/3/10	58.6	58.6				3.5	3.5								
		NDC2.1.2	5.1	2/25/11	54.9	66.5													
			6.1		71.5														
			7.1		73.1														
		NDC2.2	NDC2.2.1	1.1	12/1/09	41.0	28.8		74.4		14.3		12.0				3.0		
				2.1		0.0													
				3.1		29.7													
	3.2			44.3		14.3													
	4.1			9/2/10	139.4	135.4	9.9			10.9	3.1			3.0					
	5.1				144.4		11.9				3.2								
	6.1				122.4						3.2								
	6.2										2.7								
	NDC2.3	NDC2.3.1	1.1	9/6/10	206.7	193.5	123.7			15.5	25.1			25.1	2.3			2.3	2.3
			1.2		215.2					19.5					2.4				
			2.1		187.7					40.4			2.4						
			3.1		164.2								2.2						
			4.1	12/4/10	19.9	30.6													
			5.1		0.0														

\* Differentiation plate. First digit identifies the plate of NPCs differentiated for 3 weeks, prior to FACS purification. The second digit identifies the well of purified neurons that was cultured for an additional 5 days before harvesting  
† Observed amount for each corresponding well of purified neurons  
‡ Mean amount for each FACS purification batch  
§ Mean amount for each iPSC line (displayed in Supplementary Fig. 11)  
¶ Mean amount for each patient (displayed in Fig. 2 and Supplementary Table 4)

Table S5, continued

Patient	iPSC line	NPC line	Diff. plate*	FACS purification date	Aβ/lysate (pg/mg)†	Aβ purif. mean ‡	Aβ iPSC line mean §	Aβ patient mean¶	aGSK3β (% of total) †	aGSK3β purif. mean‡	aGSK3β iPSC line mean§	Active GSK3β patient mean¶	pTau/ tTau (units/ng)†	pTau/ tTau purif. mean‡	pTau/ tTau iPSC line mean§	pTau/ tTau patient mean¶			
sAD1	sAD1.1	sAD1.1.1	1.1	12/15/09	102.3	110.2	99.9	94.5	24.4	27.4	27.4	23.9	3.9	3.9	3.9	4.9			
			2.1		98.4				26.9				3.7						
			3.1		129.9				30.8				4.2						
			3.2										4.0						
		sAD1.1.2	4.1	9/8/10	94.8	92.2													
			4.2		90.2														
			5.1		79.2														
			6.1		104.7														
		sAD1.2	sAD1.2.1	1.1	3/19/10	30.4			39.7	73.8				19.8				3.1	4.9
				2.1		46.5											2.6		
				3.1		42.0											3.7		
				4.1	9/7/10	111.8			99.3		20.1		19.8				7.0	6.7	
	4.2			76.3		19.5					6.5								
	5.1			82.6		19.7													
	6.1			126.6															
	sAD1.3			sAD1.3.1	1.1	4/3/10			131.7		124.8		109.9		31.5		24.7	24.7	
		2.1	108.1		29.2		7.2												
		3.1	134.8		13.4		5.0												
		3.2					5.6												
		4.1	10/7/10		87.5	98.7													
		5.1			80.3														
		6.1			124.5														
		6.2			102.7														

\* Differentiation plate. First digit identifies the plate of NPCs differentiated for 3 weeks, prior to FACS purification. The second digit identifies the well of purified neurons that was cultured for an additional 5 days before harvesting  
† Observed amount for each corresponding well of purified neurons  
‡ Mean amount for each FACS purification batch  
§ Mean amount for each iPSC line (displayed in Supplementary Fig. 11)  
¶ Mean amount for each patient (displayed in Fig. 2 and Supplementary Table 4)

Table S5, continued

d

Patient	iPSC line	NPC line	Diff. plate*	FACS purification date	Aβ/lysate (pg/mg)†	Aβ purif. mean ‡	Aβ iPSC line mean §	Aβ patient mean¶	aGSK3β (% of total) †	aGSK3β purif. mean‡	aGSK3β iPSC line mean§	Active GSK3β patient mean¶	pTau/tTau (units/ng)†	pTau/tTau purif. mean‡	pTau/tTau iPSC line mean§	pTau/tTau patient mean¶		
sAD2	sAD2.1	sAD2.1.1	1.1	4/3/10	229.9	172.5	206.4	299.9	33.2	35.4	35.4	36.4	8.0	7.3	7.3	7.8		
			2.1		135.8				36.9				7.0					
			3.1		158.3				36.0				7.4					
			3.2		165.9								7.0					
			4.1	10/7/10	257.7	240.2												
			5.1		247.8													
			6.1		200.2													
			6.2		255.2													
		sAD2.2	sAD2.2.1	1.1	12/4/09	237.6	240.7		339.8	28.3	24.3	24.3		5.6	5.0			
				2.1		227.9				19.8			4.7					
				3.1		256.4				24.8			6.5					
				4.1	2/28/10	208.3	204.4					4.7	4.4					
				5.1		185.4				4.1								
				6.1		219.4												
				7.1	9/1/10	704.4	691.4											
				8.1		678.5												
	sAD2.3	sAD2.3.1	1.1	4/1/10	207.4	233.1	353.5		50.8	49.5	49.5	12.3	11.1	11.1				
			2.1		216.0				47.6			8.7						
			3.1		275.8				50.0			11.5						
			3.2									12.0						
			3.3	2/25/11	401.6	425.7												
			4.1		434.3													
			5.1		430.1													
			6.1		417.2													
			6.2		445.4													
			sAD2.4	sAD2.4.1	1.1	3/22/11			395.9	375.3	375.3	42.1	40.7	40.7	8.1		6.9	6.9
					2.1				450.2			40.3			6.3			
					3.1				414.9			39.7			8.1			
	4.1	240.1					5.0											
	sAD2.5	sAD2.5.1	1.1	3/22/11	433.3	381.0	381.0		42.9	42.7	42.7	7.7	7.3	7.3				
			2.1		431.4				41.8			7.4						
			3.1		423.2				43.4			6.9						
4.1			236.1					7.2										

\* Differentiation plate. First digit identifies the plate of NPCs differentiated for 3 weeks, prior to FACS purification. The second digit identifies the well of purified neurons that was cultured for an additional 5 days before harvestin  
† Observed amount for each corresponding well of purified neurons  
‡ Mean amount for each FACS purification batch  
§ Mean amount for each iPSC line (displayed in Supplementary Fig. 11)  
¶ Mean amount for each patient (displayed in Fig. 2 and Supplementary Table 4)

Table S5, continued

Patient	iPSC line	NPC line	Diff. plate*	FACS purification date	Aβ/lysate (pg/mg)†	Aβ purif. mean ‡	Aβ iPSC line mean §	Aβ patient mean¶	aGSK3β (% of total) †	aGSK3β purif. mean‡	aGSK3β iPSC line mean§	Active GSK3β patient mean¶	pTau/ tTau (units/ng)†	pTau/ tTau purif. mean‡	pTau/ tTau iPSC line mean§	pTau/ tTau patient mean¶					
APP <sup>DP1</sup>	APP <sup>DP1.1</sup>	APP <sup>DP1.1.1</sup>	1.1	5/4/09	245.0	262.8	247.6	275.9			26.5	28.6	6.0	5.9	7.4	8.4					
			2.1		280.7					5.7											
			3.1	10/14/09	187.1	209.2			24.1	26.5				8.8							
			4.1		205.3				29.5				9.4								
			5.1		235.2				25.9				8.3								
			6.1	10/5/10	172.9	289.9															
			7.1		406.8																
			APP <sup>DP1.2</sup>	APP <sup>DP1.2.1</sup>	1.1	3/8/10			720.4	737.1			393.0					30.2		9.4	14.1
					2.1				753.8					9.4							
					3.1	9/2/10			151.6	165.7				34.7			30.2		16.1	15.6	
					4.1				149.2					27.5					16.0		
					5.1				196.4					28.5					14.8		
					6.1	4/11/11			393.1	389.7											
					7.1				386.4												
	APP <sup>DP1.3</sup>	APP <sup>DP1.3.1</sup>	1.1	2/16/10	202.8	207.7	187.2				29.1		3.2	3.7	3.7						
			2.1		212.7					4.2											
			3.1	3/8/10	46.3	78.4			27.6	29.1				3.7							
			4.1		78.0				33.0				4.0								
			5.1		111.0				26.8				3.4								
			6.1	4/11/11	251.9	329.9															
			7.1		408.0																

\* Differentiation plate. First digit identifies the plate of NPCs differentiated for 3 weeks, prior to FACS purification. The second digit identifies the well of purified neurons that was cultured for an additional 5 days before harvesting  
† Observed amount for each corresponding well of purified neurons  
‡ Mean amount for each FACS purification batch  
§ Mean amount for each iPSC line (displayed in Supplementary Fig. 11)  
¶ Mean amount for each patient (displayed in Fig. 2 and Supplementary Table 4)

Table S5, continued

f

Patient	iPSC line	NPC line	Diff. plate*	FACS purification date	Aβ/lysate (pg/mg)†	Aβ purif. mean ‡	Aβ iPSC line mean §	Aβ patient mean¶	aGSK3β (% of total) †	aGSK3β purif. mean‡	aGSK3β iPSC line mean§	Active GSK3β patient mean¶	pTau/ tTau (units/ng)†	pTau/ tTau purif. mean‡	pTau/ tTau iPSC line mean§	pTau/ tTau patient mean¶				
APP <sup>bp</sup> 2	APP <sup>bp</sup> 2.1	APP <sup>bp</sup> 2.1.1	1.1	3/3/10	35.9	24.2	252.5	356.8			41.7	41.3			6.6	7.7				
			2.1		17.2															
			3.1		19.4															
			4.1	3/13/10	140.9	119.9							4.9							
			5.1		103.8						4.4									
			6.1		115.0						5.3									
			7.1	9/4/10	574.7	613.3			37.7	41.7			8.4							
			8.1		582.8				38.8		8.3									
			9.1		682.4				48.7		8.5									
			APP <sup>bp</sup> 2.2	APP <sup>bp</sup> 2.2.1	1.1	3/1/10			537.7	277.9	507.1						49.4			8.8
					2.1				18.1											
					3.1	3/28/10			81.2	70.7										
					4.1				60.0											
					5.1				70.9											
					6.1	9/1/10			1016.9	949.0			53.0	49.4			9.6	8.8		
	7.1	956.2			49.3		8.2													
	8.1	978.3			45.7		7.4													
	8.2	844.5					9.9													
	APP <sup>bp</sup> 2.3	APP <sup>bp</sup> 2.3.1	1.1	2/21/10	169.3	132.8	310.8			32.7			7.6							
			2.1		96.2															
			3.1	3/24/10	82.0	88.3														
			4.1		81.2															
			5.1		101.6															
			6.1	9/28/10	570.8	566.6		33.3	32.7	7.2	7.6									
			7.1		559.2			32.5		8.5										
			8.1		571.6			32.3		6.9										
			8.2		565.0					7.9										

\* Differentiation plate. First digit identifies the plate of NPCs differentiated for 3 weeks, prior to FACS purification. The second digit identifies the well of purified neurons that was cultured for an additional 5 days before harvesting  
† Observed amount for each corresponding well of purified neurons  
‡ Mean amount for each FACS purification batch  
§ Mean amount for each iPSC line (displayed in Supplementary Fig. 11)  
¶ Mean amount for each patient (displayed in Fig. 2 and Supplementary Table 4)